• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Spotting undiagnosed significant liver fibrosis in the general population: impact on subsequent clinical care: Editorial on "Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis".

作者信息

Peng Nana, Wang Mary Yue, Song Sherlot Juan, Yip Terry Cheuk-Fung

机构信息

Medical Data Analytics Center, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong.

State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.

出版信息

Clin Mol Hepatol. 2025 Jan;31(1):256-260. doi: 10.3350/cmh.2024.0737. Epub 2024 Sep 3.

DOI:10.3350/cmh.2024.0737
PMID:39228070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11791585/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a06/11791585/7ecb5332ffe1/cmh-2024-0737f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a06/11791585/7ecb5332ffe1/cmh-2024-0737f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a06/11791585/7ecb5332ffe1/cmh-2024-0737f1.jpg

相似文献

1
Spotting undiagnosed significant liver fibrosis in the general population: impact on subsequent clinical care: Editorial on "Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis".在普通人群中发现未诊断出的显著肝纤维化：对后续临床护理的影响：关于“普通人群中临床显著肝纤维化的患病率：系统评价和荟萃分析”的社论
Clin Mol Hepatol. 2025 Jan;31(1):256-260. doi: 10.3350/cmh.2024.0737. Epub 2024 Sep 3.
2
Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis.一般人群中临床显著肝纤维化的患病率：系统评价和荟萃分析。
Clin Mol Hepatol. 2024 Sep;30(Suppl):S199-S213. doi: 10.3350/cmh.2024.0351. Epub 2024 Jul 30.
3
Towards unification of liver stiffness measurement cutoffs: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".迈向肝硬度测量临界值的统一：关于“振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者晚期肝纤维化中的最佳临界值：一项系统评价和荟萃分析”的社论
Clin Mol Hepatol. 2025 Jan;31(1):264-267. doi: 10.3350/cmh.2024.0766. Epub 2024 Sep 20.
4
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".评估代谢功能障碍相关脂肪性肝病中晚期纤维化的重要工具：关于“振动控制瞬时弹性成像和磁共振弹性成像诊断非酒精性脂肪性肝病患者晚期肝纤维化的最佳截断值：一项系统评价和荟萃分析”的社论
Clin Mol Hepatol. 2025 Jan;31(1):277-280. doi: 10.3350/cmh.2024.0823. Epub 2024 Oct 11.
5
Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis.非酒精性脂肪性肝病无创性纤维化进展的药物治疗疗效：系统评价和网络荟萃分析。
Eur J Gastroenterol Hepatol. 2023 Jan 1;35(1):102-111. doi: 10.1097/MEG.0000000000002463. Epub 2022 Nov 17.
6
Transient elastography for assessing liver fibrosis in autoimmune liver diseases: Excellent performance but limited details: Editorial on "Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis".瞬时弹性成像评估自身免疫性肝病肝纤维化：性能卓越但细节有限：关于“振动控制瞬时弹性成像对自身免疫性肝病肝纤维化分期的诊断准确性：一项系统评价和荟萃分析”的述评
Clin Mol Hepatol. 2025 Jan;31(1):275-276. doi: 10.3350/cmh.2024.0827. Epub 2024 Oct 8.
7
Correspondence to editorial on "Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".致关于“振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者晚期肝纤维化中的最佳截断值：一项系统评价和荟萃分析”的社论的信函
Clin Mol Hepatol. 2025 Jan;31(1):e52-e54. doi: 10.3350/cmh.2024.0815. Epub 2024 Sep 24.
8
Correspondence to editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis".致关于“振动控制瞬时弹性成像和磁共振弹性成像在诊断非酒精性脂肪性肝病患者晚期肝纤维化中的最佳截断值：一项系统评价和荟萃分析”的社论的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e61-e63. doi: 10.3350/cmh.2024.0878. Epub 2024 Oct 15.
9
Ultrasound Shear Wave Elastography for Liver Disease. A Critical Appraisal of the Many Actors on the Stage.用于肝脏疾病的超声剪切波弹性成像：对该领域众多参与者的批判性评估
Ultraschall Med. 2016 Feb;37(1):1-5. doi: 10.1055/s-0035-1567037. Epub 2016 Feb 12.
10
[Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography].[用于评估肝纤维化的非侵入性成像检查：振动控制瞬时弹性成像]
Korean J Gastroenterol. 2024 Nov 25;84(5):201-205. doi: 10.4166/kjg.2024.120.

引用本文的文献

1
Correspondence to editorial on "Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis".致关于“普通人群中具有临床意义的肝纤维化患病率：一项系统评价和荟萃分析”的社论的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e48-e51. doi: 10.3350/cmh.2024.0777. Epub 2024 Sep 11.

本文引用的文献

1
Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis.一般人群中临床显著肝纤维化的患病率：系统评价和荟萃分析。
Clin Mol Hepatol. 2024 Sep;30(Suppl):S199-S213. doi: 10.3350/cmh.2024.0351. Epub 2024 Jul 30.
2
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
3
Hepatitis C.
丙型肝炎。
Lancet. 2023 Sep 23;402(10407):1085-1096. doi: 10.1016/S0140-6736(23)01320-X.
4
Diagnostic and prognostic performance of the SAFE score in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中 SAFE 评分的诊断和预后性能。
Liver Int. 2024 Jan;44(1):15-26. doi: 10.1111/liv.15718. Epub 2023 Aug 31.
5
Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.通过自动化纤维化评分计算和电子提醒信息检测 2 型糖尿病患者的晚期肝病的临床护理路径：一项随机对照试验。
Gut. 2023 Nov 24;72(12):2364-2371. doi: 10.1136/gutjnl-2023-330269.
6
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study.2022年全球乙型肝炎的流行率、照护流程及预防覆盖率：一项建模研究
Lancet Gastroenterol Hepatol. 2023 Oct;8(10):879-907. doi: 10.1016/S2468-1253(23)00197-8. Epub 2023 Jul 27.
7
The Global Burden of Liver Disease.《全球肝脏疾病负担》
Clin Gastroenterol Hepatol. 2023 Jul;21(8):1978-1991. doi: 10.1016/j.cgh.2023.04.015. Epub 2023 Apr 28.
8
Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis.2 型糖尿病与非酒精性脂肪性肝病相关肝脏事件的持续时间：一个里程碑式分析。
Hepatology. 2023 Dec 1;78(6):1816-1827. doi: 10.1097/HEP.0000000000000432. Epub 2023 May 1.
9
Global epidemiology of cirrhosis - aetiology, trends and predictions.全球肝硬化的流行病学：病因、趋势和预测。
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. doi: 10.1038/s41575-023-00759-2. Epub 2023 Mar 28.
10
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.